Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicentre, Open-label, Dose-escalation and Expansion Study to Determine a Recommended Phase 2 Dose (RP2D) of DT-9081 in Participants With Advanced Solid Tumours

NCT05582850 is registered in ClinicalTrials.gov with Domain Therapeutics SA as lead sponsor.

NCT NCT05582850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05582850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicentre, Open-label, Dose-escalation and Expansion Study to Determine a Recommended Phase 2 Dose (RP2D) of DT-9081 in Participants With Advanced Solid Tumours
Lead sponsor
Domain Therapeutics SA
Phase
Phase 1
Overall status
Terminated
Start date
November 24, 2022
Completion date
April 8, 2025
Enrollment
29 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult